Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
Semin Immunol
; 28(1): 45-53, 2016 02.
Article
en En
| MEDLINE
| ID: mdl-26710685
Adoptive T cell-based immunotherapies can mediate complete and durable regressions in patients with advanced cancer, but current response rates remain inadequate. Maneuvers to improve the fitness and antitumor efficacy of transferred T cells have been under extensive exploration in the field. Small non-coding microRNAs have emerged as critical modulators of immune system homeostasis and T cell immunity. Here, we summarize recent advances in our understanding of the role of microRNAs in regulating T cell activation, differentiation, and function. We also discuss how microRNA therapeutics could be employed to fine-tune T cell receptor signaling and enhance T cell persistence and effector functions, paving the way for the next generation of adoptive immunotherapies.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Inmunoterapia Adoptiva
/
Vacunas contra el Cáncer
/
MicroARNs
/
ARN Pequeño no Traducido
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Semin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2016
Tipo del documento:
Article
Pais de publicación:
Reino Unido